Evaluation of the treatment of cutaneous leishmaniasis with Epigallocatechin Gallate

Evaluation of the treatment of cutaneous leishmaniasis with Epigallocatechin Gallate, as topical supplemental therapy (A RCT study)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180526039848N2

Enrollment

Registered

2021-04-27

Start date

2020-12-20

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cutaneous leishmaniasis. Cutaneous leishmaniasis

Interventions

Intervention 1: Intervention group: Includes ten people with EGCGin USP hydrophilic ointment (2%) in one of the wounds plus glucantime to increase the effectiveness compared to the other wound of the

Eligibility

Sex/Gender

All

Age

15 Years to 60 Years

Inclusion criteria

Inclusion criteria: There are at least two lesions, in one case intervention + glucantime and in the other lesion only glucantime is prescribed. 15 to 60 years Skin lesions at least one centimeter in size Leishmaniasis confirmed by a parasitologist consent signature

Exclusion criteria

Exclusion criteria: People who do not use the drug according to the plan People who do not go to the clinic on the scheduled days

Design outcomes

Primary

Measure	Time frame
Lesion size (diameter). Timepoint: Day of 7? 14? 21? 28? 35? 42. Method of measurement: Image J software.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElham Moghaddase

Mashhad University of Medical Sciences

moghaddase@mums.ac.ir+98 51 3800 2406

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026